- 1 Reevaluating the Role of ACE Inhibitors in Skin Fibrosis Risk: Evidence from
- 2 Mendelian Randomization
- 3 Running title: ACEI does not decrease skin fibrosis
- 4 Yangyang Wei^{1,2,*}, Ziqi Wan^{2,*}, Yiwen Jiang², Zhengye Liu³, Ming Yang^{4,#}, Jieying
- 5 $Tang^{1,\#}$
- 6 1. Department of Plastic Surgery, Beijing Tsinghua Changgung Hospital, School of
- 7 Clinical Medicine, Tsinghua University, Beijing, China.
- 8 2. Eight-year Program, Peking Union Medical College and Chinese Academy of
- 9 Medical Sciences, Beijing, China.
- 10 3. Department of Plastic and Aesthetic Center, The First Affiliated Hospital, School of
- 11 Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
- 12 4. Department of Cardiology, Peking Union Medical College Hospital, Chinese
- 13 Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
- 15 *Contributed equally

22

24

27

- [#]Corresponding authors: Dr. Jieying Tang, Department of Plastic Surgery, Beijing
- 17 Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University,
- 18 Beijing, China. Tel: 8613811271136. Email: tjya01274@btch.edu.cn
- 19 Dr. Ming Yang, Department of Cardiology, Peking Union
- 20 Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union
- 21 Medical College, Beijing, China. Tel: 86-10-69155005. Email: yangming@pumch.cn
- Fund: Beijing Tsinghua Changgung Hospital Fund (Grant No. 12023C1004)
- 25 Interest Statement
- All of us declare that we have no competing interests.
- 28 Ethical Approval
- 29 Not Applicable.
- NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. 30

Ethnic Statement

32 Not Applicable.

31

33

34

37

38

Data Availability Statement

- 35 Sources of full summary GWAS datasets were listed in Supplementary File 2. No new
- data was generated from recurrent study.

Author Contributions

- 39 Conceptualization: The study was initially conceptualized by YW, ZW and JT. They
- 40 developed the research idea and designed the overall framework of the study.
- 41 Methodology: Methodology was developed by ZW, YJ and ZL. They were
- responsible for designing and implementing the experimental protocols.
- 43 Investigation: Investigation and data collection were primarily conducted by YW, ZW
- and JT. They carried out the experiments and gathered the necessary data.
- Data Analysis: Data analysis was performed by YW and ZW. They processed the raw
- 46 data and conducted the statistical analyses.
- 47 Writing Original Draft Preparation: The original draft of the manuscript was written
- 48 by YW and ZW. They prepared the initial version of the paper, including the
- 49 introduction, methods, results, and discussion sections.
- Writing Review & Editing: Review and editing of the manuscript were conducted by
- 51 YJ, ZL, MY and JT. They reviewed the draft for important intellectual content and
- made revisions.
- 53 Funding Acquisition: Funding for the study was secured by MY and JT. They applied
- for and obtained the necessary grants to support the research.
- 55 Supervision: Supervision of the entire project was provided by MY and JT. They
- oversaw the project progress and provided guidance throughout the research.
- 57 Project Administration: Project administration, including coordination of research
- activities and maintaining timelines, was managed by MY and JT.

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

Manuscript Count: 3862 Figure count: 4, Table count: 7 **Abstract:** Background: Skin fibrosis, characterized by excessive extracellular matrix deposition, leads to hypertrophic scars and keloids, which are both common and often detrimental conditions. Angiotensin-converting enzyme (ACE) inhibitors have shown promise in animal studies and limited clinical trials for reducing scar formation. However, the causal relationship between ACE inhibition and skin fibrosis remains unclear. **Methods:** This study employed two-sample Mendelian randomization (MR) analysis to investigate the causal effect of ACE inhibition on skin fibrotic diseases. We utilized genetic variants associated with serum ACE levels, ACE inhibition, and effect of decreasing blood pressure by ACE inhibition as instrumental variables. We analyzed the association between these exposures and the incidence of skin fibrosis, hypertrophic scars, and keloids using various MR methods. Results: We found no significant causal relationship between genetically proxied serum ACE levels, or local skin tissue ACE expression and the risk of skin fibrosis, hypertrophic scars, or keloids. Additionally, there was no direct causal relationship between the effect of ACE inhibitors on blood pressure reduction and the risk of skin fibrotic diseases. However, we observed a significant negative association between systolic blood pressure (SBP) and the risk of hypertrophic scars. Conversely, we found a positive association between β -blockers and the risk of skin fibrosis. Conclusion: Our findings suggest that ACE inhibitors do not have a direct causal effect on the risk of skin fibrotic diseases, including hypertrophic scars and keloids. This challenges the potential of ACE inhibitors as a therapeutic option for preventing or treating these conditions. **Keywords:** skin fibrosis, angiotensin-converting enzyme, Mendelian Randomization

Introduction

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

Skin fibrosis involves the deposition of extracellular matrix of dermis, a process that can occur in all kinds of wound healing of injuries. Hypertrophic scars and keloids are two common types of excessive scar caused by skin fibrosis. Hypertrophic scar is that scar proliferation stays within the limits of the edges of the initial scar, whereas keloid is characterized by pseudo-tumor proliferation extending over the edges of the initial wound. ^{1,2} These conditions are highly prevalent in population, affecting patients with all kinds of skin wounds including surgical ones. Excessive scars can lead to unexpected changes in appearance, causing pain and functionally impairing patients' quality of life. Current conservative treatments for excessive scarring include cryotherapy, corticosteroid injections or tapes, chemotherapy and surgery. 1 Few interventions target the molecular mechanism specifically. Mechanisms of skin fibrosis are not completely understood, involving intricate pathways such as inflammatory reactions and hormone regulation.³ Angiotensin-converting enzyme (ACE) is a well-known molecule that can increase blood pressure by converting angiotensin I to angiotensin II within renin-angiotensin system (RAS). ⁴ Angiotensin II can bind to the Type I angiotensin receptor (AT1 receptor) and initiate the complex downstream effects. The serum ACE has been demonstrated to be critical in the development and progression of fibrosis in multiple organs, including heart, liver, and kidney. 5-9 Effects of angiotensin II include the increase of collagen and fibronectin synthesis, which are ultimately associated with fibrosis in different organs. Given its pivotal role in the regulation of RAS, ACE has been inferred to be a therapeutic potential target for skin fibrosis due to its effects on inflammatory reaction and homeostasis of skin healing. ⁵ Animal studies have provided evidence that ACE gene deficiency decreases scar formation in rats effectively. 11,12 A study on rabbits also demonstrated that oral ACE inhibitor (Enalapril) effectively decreased hypertrophic scars on rabbit ears. ¹³ And several clinical researches reported the effectiveness of ACE inhibitors in decreasing the formation of excessive scars. A retrospective chart review study on bilateral breast reduction surgery (n = 961) discovered patients with an ACE inhibitors or angiotensin

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

receptor blocker (ARB) exhibited a significantly lower incidence of being diagnosed as hypertrophic scar. ¹⁴ Furthermore, in another double-blind clinical trial conducted in Iran population (n = 30), patients treated with local topical Enalapril exhibited hypertrophic scars with significantly smaller mean thickness than the placebo-treated ones, along with a significantly lower mean itching score. ¹⁵ However, the sample sizes of the clinical trial were insufficiently large and only involved Iran population. The researches were limited by study design. ¹⁶ Mendelian randomization is a method to explore the causal effect of two traits (exposure and outcome) via genetic instrumental variants (IVs). 17, 18 It holds three assumptions: 1) IVs are extensively associated with exposure; 2) There are no confounders between the instruments and outcome; 3) IVs' effect on outcome can only be exerted via exposure. MR provides a convenient method for exploring the causal relationship between phenotypes with evidence of nearly the same level as randomized controlled trial (RCT) when conducting RCTs is challenging. However, there has not been an exploration of the causal relationship between ACE inhibition and diseases related to skin fibrosis using MR analysis. Here we aimed to explore the causal effect of ACE inhibitors (ACEi) on excessive scars related to skin fibrosis, including hypertrophic scar and keloids, by two-sample MR analysis from multiple dimensions. We investigated the causal effects of genetically proxied serum ACE, inhibition of ACE and systolic and diastolic blood pressure (SBP/DBP), respectively, on the incidence of skin fibrosis. And we further explored the causal effects of SBP, DBP, β blockers and calcium channel blockers, angiotensin receptor blockers and excessive scarring related to skin fibrosis. Methods Study design The study design is illustrated in Figure 1. To investigate the causal effect of ACE inhibitors on skin fibrotic diseases, we conducted MR analysis with exposures of serum ACE, genetically-proxied inhibition of serum ACE, and effect of increasing SBP and DBP by ACE, respectively. Furthermore, we employed Summary-based MR

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

analysis (SMR) to explore the causal effect of ACE expression in local skin tissue on skin fibrotic diseases. Considering that the target of Type 1 angiotensin II receptor blockers (ARBs), AT1 receptor is the main downstream receptor of angiotensin II, we investigated causal relationship between ARBs and skin fibrotic diseases. Moreover, considering that blood pressure might be a risk factor of skin fibrotic diseases ^{19, 20}, in order to investigate whether the effect of ACE on skin fibrotic diseases is through the blood pressure, we also investigated the causal effect of blood pressure and targets of other anti-hypertension drugs (β blockers and calcium channel blockers, abbreviated as BBs and CCBs) on skin fibrotic diseases through MR analysis. All the genetic IVs were chosen on autosomes in order to avoid sex-specific effects. ²¹ **Data sources** For serum ACE concentration, we initially utilized single SNP "rs4343" as IV of serum ACE. Rs4343 is located in the ACE gene, which is extensively associated with an indel known as Alu in the 16th intron and then associated with expression of ACE. 23 Rs4343 exhibits the strongest association with serum ACE inhibition (p = 1.53e-213) among SNPs according to the group of IV proxied serum ACE inhibition. 24 Additionally, we utilized another group of IVs from a protein quantitative trait locus (pQTL) research of serum ACE of 35,275 individuals with Island ancestry. The population shares a similar age, gender, and BMI structure with the UKB corhort. ²² Furethermore, in order to supply more evidence of the causal relationship between serum ACE inhibition and skin fibrotic diseases, we utilized a group of IVs (including rs4343) to proxy serum ACE inhibition from a previous MR study, which was from a pQTL of 4,174 individuals from Genetic Epidemiology Research on Adult Health and Aging. 24 We initially employed single SNP "rs4291" to proxy the effect of ACE inhibition on decreasing SBP. Rs4291 is located on the promoter of ACE gene, which is also extensively associated with the indel Alu and exhibits the most significant correlation with the effect of ACE inhibition on decreasing SBP. ²⁵ Its effect was from a meta-analysis of GWAS covered 757,601 individuals with European ancestry of UKB individuals and International Consortium of Blood Pressure GWAS. 26 Then we

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

utilized another group of IV associated with the decrease effect of SBP by ACE (containing 2 SNPs) extracted by a previous MR study, whose effect was from the mentioned meta-analysis covered 757,601 individuals. ²⁴ We accessed GWAS data of SBP and DBP from a previous study encompassing 469,767 and 490,469 individuals within European ancestry in UK Biobank cohort. ²⁸ And we selected SNPs that have strong relevance (p < 5e-8) with serum ACE according to the mentioned pQTL, and extracted their effects on SBP or DBP from these two GWAS datasets of SBP and DBP. From this set of SNPs, we further included SNPs that also had strong relevance of SBP or DBP (p < 5e-6) to proxy the ACE-induced increase of SBP or DBP. For local expression of ACE gene in skin tissue, summary data of expression quantitative trait locus research (eQTL) of local tissue was downloaded from GTEx v8 data. ²⁹ Considering the influence of sunshine exposure on skin, we employed summary data from suprapubic skin and skin of lower leg to represent skin with and without sunshine exposure respectively. In order to investigate the potential causal effect of anti-hypertension drugs (BBs and CCBs) on skin fibrotic diseases, we extracted IVs proxied the effect of increasing SBP by BB and CCB drug target gene (ADRB1 for BB, CACNA1D, CACNA1F, CACNA2D1, CACNA2D2, CACNA1S, CACNB1, CACNB2, CACNB3, CACNB4, CACNG1, and CACNA1C for CCB) from a previous study of MR analysis. ²⁶ IV for effect of decreasing SBP by ARBs target gene (type 1 angiotensin II receptor, ATI) were extracted from another MR study. ²⁷ All the effect data to SBP was from the meta-analysis of GWAS covered 757,601 individuals All the detailed information for exposures were listed in Table 1. We employed GWAS datasets for hypertrophic scar, keloid, skin fibrosis, and scar condition (defined as a fibrotic scar that could not be differentiated as keloid or hypertrophic scar). All the data were sourced from populations of European ancestry. Among these data for hypertrophic scar and one data of skin fibrosis and scar condition were from FinnGen, whereas data for keloid and the other data of skin fibrosis and scar condition were from UK Biobank. The detailed information for each dataset was listed in Table 2. 28, 30

210 MR IVs selection 211 For IVs of multiple SNPs proxied effects of target genes (ACE, target genes for BBs, 212 CCBs and ARBs), we selected SNPs with strong relevance (p < 5e-8) to respective 213 exposures. For serum ACE and serum ACE inhibition, we selected SNPs within \pm 100 214 kb of ACE gene. For effects of decreasing SBP by BBs and CCBs, we selected SNPs within corresponding genes or in the promoters and enhancers. ²⁶ IV for ARB was 215 216 selected in the drug-targeted genes associated with BP at a genome-wide significant level, which was identified in DrugBank. 27 Promoter and enhancer regions of 217 218 corresponding drug targets were identified using the GeneHancer database in the 219 GeneCards online platform. Subsequently, we decreased the linkage disequilibrium of the IVs by clumping on condition that genetic distance > 10,000 kb and $r^2 < 0.1$. 220 From the GWAS data of SBP and DBP, we selected SNPs with strong relevance (p < 221 5e-8). ³¹ Then SNPs was clumped on condition that genetic distance > 10,000 kb and 222 223 $r^2 < 0.0001$ to eliminate linkage disequilibrium. 224 For IV of effect of serum ACE on decreasing SBP and DBP, we extracted SNPs with 225 extensive relevance for serum ACE (data from pQTL of serum ACE, p < 5e-8) and 226 SBP or DBP (data from GWAS of SBP and DBP, p < 5e-6, for no SNP existed on 227 condition that p < 5e-8). Then we selected SNPs within \pm 100 kb of ACE gene and clumped on condition that genetic distance > 10,000 kb and $r^2 < 0.1$ thereby reducing 228 229 linkage disequilibrium. 230 For all IVs that will be used in MR analysis, we harmonized effects of SNPs on 231 exposure and outcome to ensure effects relative to the same allele and exclude 232 palindromic SNPs with intermediate allele frequencies (> 0.42). In order to avoid 233 potential confounding, we delete SNPs strongly related (p < 5e-8) to outcomes (skin fibrosis, hypertrophic scar and keloid) by investigating all the SNPs on PhenoScanner 234 database (http://www.phenoscaner.medschl.cam.ac.uk/) . ³² For the exposure of SBP, 235 DBP and the effect on SBP/DBP by ACEi, ARB, BBs and CCBs included UKB 236 237 cohorts, MR analysis with sample overlapping (outcome data from UKB cohorts) was 238 eliminated by checking the sample sources of exposures and outcomes from different

239

cohorts.

R (Version 4.3.3, The R Foundation for Statistical Computing Platform, Vienna,

Statistics

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

Austria) was used to perform MR analysis and subsequent sensitivity analysis. R packages "dplyr", "TwoSampleMR" (Version 0.6.4) and "ieugwasr" 33 were used to input, clump and analyze data. To explore the causal relationship of exposures and outcomes, when only one SNP existed in IV, we used method Wald ratio, while when two or more SNPs existed, we used method inverse variance weighted (IVW) including random effects IVW (IVW-MRE) and fixed effects IVW (IVW-FE). 34 In order to obtain more reference, we performed MR analysis by the weighted-median ³⁵, MR Egger ³⁶, simple-mode and weighted-mode method as secondary analysis methods. In MR analysis between drug targets (ACEi, ARBs, BBs and CCBs), we didn't employ the MR Egger due to the confounding effects of IVs against the INSIDE assumptions of MR Egger. Cochran's Q statistic was used to estimate the heterogeneity of IVs. If no significant heterogeneity exists (pQ < 0.05), we referred to results from the fixed-effects IVW MR analysis. If significant heterogeneity exists (pQ < 0.05), we referred to results from the random-effects IVW MR analysis. And we tested the pleiotropy of SNPs by the intercept value from the MR Egger method ³⁶⁻³⁸. The p value less than 0.05 indicated significant pleiotropy. If IVs of exposure were with pleiotropy, the analysis results would be excluded. F statistics were used to evaluate the risk of weak instrument bias. We used formula that $F = (N-k-1)/k*r^2/(1-r^2)$ to calculate F. Among those N is the sample size of GWAS research, k is the amount of IVs. For each IV, r² was calculated as 2*MAF*(1-MAF)*β². ³⁹ If F statistics of a group of IVs was above 10, we considered that risk of weak instrument bias of IV can be ignored. An online tool (https://sb452.shinyapps.io/power/) was used to calculate the statistical power for MR analysis. 40 Summary-based MR (SMR) analysis was conducted on SMR software (version 1.3.1 for Windows system) developed by Zhang et al. 41 The software extracted SNPs within ± 5 Mb of ACE gene and with significant relevance of ACE expression in specific tissue (p < 5e-8) from the two eOTL datasets from skin tissue. We excluded SNPs whose allele frequency below 0.01. Then we reduced LD ($R^2 < 0.1$) by referring

- 270 to the 1000G European data. GWAS datasets of skin fibrotic diseases were used as
- outcomes in SMR test. Then we conducted HEIDI test to test the heterogenesis. If
- 272 pHEIDI was above 0.05, we considered the IVs exhibit no significant heterogenesis.
- 273 Results of SMR with significant heterogenesis were removed.
- 275 Results

- 276 IVs selection
- 277 All the F statistics of IVs were above 10 (listed in Table 1), and the explained variance
- of IVs were R² of 0.025% to 39%. Detailed information including amounts of SNPs,
- 279 R², F statistics, sample size and source were shown in Table 1. All the SNPs used in
- 280 MR were listed in Supplementary File 1. MR analysis whose exposure and outcome
- were with sample overlapping was removed.
- 282 Effect of serum ACE or ACE inhibition and skin fibrotic diseases
- Our analysis of MR results revealed little causal relationship between serum ACE or
- 284 ACE inhibition and skin fibrotic diseases. For single SNP (rs4343) proxied serum
- 285 ACE inhibition, results of Wald ratio showed little causal effect on skin fibrotic
- 286 diseases (hypertrophic scar: OR = 1.04, 95% CI 0.93-1.17, p = 0.46; keloid: OR = 1.12,
- 95% CI 0.83-1.52, p = 0.45; skin fibrosis and scar condition from UKB: OR = 0.95,
- 288 95% CI 0.39-2.35, p = 0.30; skin fibrosis and scar condition from FinnGen: OR = 0.93,
- 95% CI 0.81-1.07, p = 0.29). For IVs composed of multiple SNPs proxied serum ACE,
- 290 results of IVW showed little causal effect on skin fibrotic diseases (hypertrophic scar:
- OR = 0.96, 95% CI 0.86-1.07, p = 0.44; keloid: OR = 1.03, 95% CI 0.78-1.35, p = 0.49;
- skin fibrosis and scar condition from UKB: OR = 0.98, 95%CI 0.90-1.06, p = 0.56;
- skin fibrosis and scar condition from FinnGen: OR = 1.11, 95%CI 0.98-1.25, p =
- 294 0.12). For IVs containing multiple SNPs proxied serum ACE inhibition, we found
- 295 little causal effect of ACE inhibition on skin fibrotic diseases (hypertrophic scar: OR
- 296 = 0.998, 95% CI 0.924-1.078, p = 0.96; keloid: OR = 1.05, 95% CI 0.85-1.29, p = 0.66;
- skin fibrosis and scar condition from UKB: OR = 0.97, 95%CI 0.91-1.03, p = 0.33;
- skin fibrosis and scar condition from FinnGen: OR = 0.94, 95%CI 0.85-1.03, p =
- 299 0.16). Additionally, other methods also showed little causal relationship between

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

serum ACE or ACE inhibition and skin fibrotic diseases. No significant pleiotropy or heterogeneity bias was observed in these MR analysis (shown in Table 3). Effect of blood pressure by ACE or ACE inhibition and skin fibrotic diseases For both IVs of single SNP or multiple SNPs, results of Wald ratio and IVW-FE showed little causal association between the effect of ACE inhibition on decreasing blood pressure by on skin fibrotic diseases (hypertrophic scar, skin fibrosis and scar condition), all the p values were above 0.05 (shown in Table 4 and Figure 2). For MR analysis with IVs containing 2 SNPs, heterogeneity tests showed no significant heterogenetic bias existed in MR analysis (shown in Table 4). Local ACE expression and skin fibrotic diseases For skin tissue exposed to or shielded from sunshine exposure, 8 and 11 SNPs was extracted from Qtex datasets respectively to proxy local ACE expression, respectively. Notably, all the p values of SMR analysis were above 0.05 (shown in Table 5), which showed that little causal effect of ACE expression in local skin tissue on susceptibility of skin fibrotic diseases, irrespective of sunshine exposure. All the p values for HEIDI test were above 0.05 (shown in Table 5), which revealed that no significant heterogenetic bias existed. Systolic and diastolic blood pressure and skin fibrotic diseases Results of IVW-FE method showed significant negative causal effects of SBP on hypertrophic scar (OR = 0.69, 95% CI 0.54-0.89, p = 0.004). Similarly, results of MR Egger method, and IVW-MRE also demonstrated negative causal effect of SBP on hypertrophic scar, (MR Egger: OR = 0.480, 95% CI 0.244-0.947, p = 0.035; IVW-MRE: OR= 0.69, 95% CI 0.53-0.90, p = 0.007). These results collectively indicated that higher SBP level is causally associated with reduced risk of developing hypertrophic scar. However, IVW and other methods indicated little causal effect of DBP on hypertrophic scar. Additionally, no significant causal relationship was found between SBP or DBP and skin fibrosis and scar condition (shown in Table 6 and Figure 3). Sensitivity tests showed no obvious bias in pleiotropy and heterogenity. Effect of other antihypertension drugs and skin fibrotic diseases

Results of IVW-FE revealed obvious positive causal relationship between effect of

BBs on decreasing SBP and skin fibrosis and scar condition from FinnGen (OR = 1.184, 95%CI 1.033-1.357, p = 0.015), which indicated that BBs caused an increase of risk of skin fibrosis. Heterogeneity and pleiotropy tests for both MR analysis showed little heterogeneity and horizontal pleiotropy (shown in Table 7 and Figure 4). However, results of IVW-MRE indicated little causal relationship between effect of BBs on decreasing SBP and hypertrophic scar, for which heterogenesis test revealed significant heterogeneity of this result (pQ = 0.008). And results of IVW-FE showed little causal relationship between effects of CCBs on decreasing SBP and hypertrophic scar or skin fibrosis and scar condition, either. Similarly, results of simple mode, weighted mode and weighted median methods for MR analysis showed similar conclusions of the little causal effect of CCBs on hypertrophic scar or skin fibrosis and scar condition. In heterogeneity and pleiotropy test, except MR between BBs and hypertrophic scar, no obvious pleiotropy and heterogeneity bias was observed. Wald ratio results found little causal relationship between blood decreasing effect of ARBs and skin fibrotic diseases (shown in Table 7 and Figure 4).

Discussion

Our study found little causal relationship of ACE inhibition on skin fibrotic diseases

using two sample MR approach. None of serum ACE, effect of decreasing SBP/DBP

by ACE inhibition or local expression of ACE gene in skin tissue was discovered

significant with causal association with the occurrence of skin fibrosis and excessive

scars including keloid and hypertrophic scar.

Nevertheless, a limited number of animal studies have suggested that ACE inhibitors

can impede progression of fibrotic skin scars when administered orally or topically,

indicating their potential as a therapeutic or preventive agent for such scars. 11-13

Additionally, a few case reports, ⁴³ the aforementioned retrospective study ¹⁴ reported

the potential of ACE inhibitor drugs (Enopril and Captopril) treatments for

hypertrophic scar and keloid on patients. However, the isolated case reports and

retrospective study did not exclude disrupting factors. Moreover, in the retrospective

study, utilization of ACE inhibitor and ARB were mixed and the dosage were not

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

unified. The aforementioned clinical trial conducted in Iran¹⁵ demonstrated the effectiveness of tropical ACE inhibitor (Enopril) on decreasing the size of hypertrophic scar. However, there was a lack of large scale clinical researches covered multiple populations which provided evidence for the efficacy of ACE inhibitors in prevention or treatment of skin fibrotic scars. A potential explanation for the discrepancies in the findings lies in the diverse statistical criteria employed to define the outcomes. While animal studies and clinical trials assessed the outcomes based on scar area, our research utilized a GWAS dataset with a binary outcome measure. Our findings indicated that ACE inhibition does not decrease the incidence of skin fibrotic diseases, which is not conflictive with the conclusion that ACE inhibitors have potential to diminish the size of skin fibrotic scar. To the best of our knowledge, there are no quantitative GWAS datasets available with phenotype specially focused on the size of fibrotic scar. Furthermore, the regulation of fibrotic proliferation in tissue by ACE is not a unidirectional process. The products of ACE, angiotensin II, exhibits dual effects on fibrosis. When angiotensin II bind to AT1 receptor, its downstream effect is to promote fibrosis by promoting inflammation reactions such as TGF-\beta synthesis. When angiotensin II binding to AT2 receptor, it can counteract inflammation reactions and suppress reactions like TGF-β synthesis. Additionally, other downstream products of angiotensin II, such as angiotensin III and angiotensin IV, also have the potential to inhibit fibrosis. 44, 45 It is noted that the expression of AT1 receptors in skin is comparatively low. RNA seq from normal tissue of different organs indicated that reads per kilobase per million mapped reads (RPKM) of AT1 receptor in skin is 0.906 ± 0.285, significantly lower than that in other tissues such as liver (21.967 \pm 2.326), kidney (5.741 \pm 1.363) and heart (2.423 ± 1.416) . ⁴⁶ These results prompt that the regulation effect by ACE in skin might be less pronounced than that in other tissue or organs. Compared to previous studies, our research had several advantages: 1) Our study provided an exploration of the association between ACE and skin fibrotic diseases with a larger sample scale in European population. 2) Our study design had

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

advantages of eliminating confounding factors as much as possible by pleiotropy test and LD diminishing. 3) Our study investigated the causal relationship beyond merely association relationship by the method of MR analysis. Our research also existed some limitations. The conclusion that ACE inhibition has little causal effect on skin fibrosis was not fully confirmed due to several limitations: 1) All the MR analysis were conducted within a single population of European descent. To validate the effect of ACE inhibition on skin fibrotic diseases in other population, GWAS researches from corresponding population were required. 2) The statistical power of MR was insufficient, necessitating GWAS studies of skin fibrotic diseases with larger sample sizes. To the best of our knowledge, exposures for effect of BBs, CCBs and ARBs lacked data of pQTLs of corresponding protein targets, and the analysis primarily included the effects of decreasing blood pressure. Consequently, the direct effects of those protein targets require further research to determine whether significant causal relationship exists between their effects and skin fibrotic diseases. Conclusion Our findings suggest that ACE inhibitors do not have a direct causal effect on the risk of skin fibrotic diseases, including hypertrophic scars and keloids. This challenges the potential of ACE inhibitors as a therapeutic option for preventing or treating these conditions. Further researches including large scale clinical trials and mechanisms researches are needed to explore the complex interplay between RAS system and skin fibrosis and the potential applications of RAS system on skin fibrotic diseases. Reference 1. Jeschke MG, Wood FM, Middelkoop E, et al. Scars. Nat Rev Dis Primers. 2023;9(1):64. Published 2023 Nov 16. doi:10.1038/s41572-023-00474-x 2. Ung CY, Warwick A, Onoufriadis A, et al. Comorbidities of Keloid and Hypertrophic Scars Among Participants in UK Biobank. JAMA Dermatol. 2023;159(2):172-181. doi:10.1001/jamadermatol.2022.5607

3. Deng CC, Hu YF, Zhu DH, et al. Single-cell RNA-seq reveals fibroblast

- 420 heterogeneity and increased mesenchymal fibroblasts in human fibrotic skin
- 421 diseases. Nat Commun. 2021;12(1):3709. Published 2021 Jun 17.
- 422 doi:10.1038/s41467-021-24110-y
- 423 4. Lopez-Sublet M, Caratti di Lanzacco L, Danser AHJ, Lambert M, Elourimi G, Persu
- 424 A. Focus on increased serum angiotensin-converting enzyme level: From
- granulomatous diseases to genetic mutations. Clin Biochem. 2018;59:1-8.
- 426 doi:10.1016/j.clinbiochem.2018.06.010
- 5. Zheng C, Huang L, Luo W, et al. Inhibition of STAT3 in tubular epithelial cells
- 428 prevents kidney fibrosis and nephropathy in STZ-induced diabetic mice. Cell Death
- 429 Dis. 2019;10(11):848. Published 2019 Nov 7. doi:10.1038/s41419-019-2085-0
- 430 6. Russo V, Papa AA, Williams EA, et al. ACE inhibition to slow progression of
- 431 myocardial fibrosis in muscular dystrophies. Trends Cardiovasc Med.
- 432 2018;28(5):330-337. doi:10.1016/j.tcm.2017.12.006
- 433 7. Shim KY, Eom YW, Kim MY, Kang SH, Baik SK. Role of the renin-angiotensin
- 434 system in hepatic fibrosis and portal hypertension. Korean J Intern Med.
- 435 2018;33(3):453-461. doi:10.3904/kjim.2017.317
- 436 8. Li S, Zhao W, Tao Y, Liu C. Fugan Wan alleviates hepatic fibrosis by inhibiting
- 437 ACE/Ang II/AT-1R signaling pathway and enhancing ACE2/Ang 1-7/Mas signaling
- pathway in hepatic fibrosis rat models. Am J Transl Res. 2020;12(2):592-601.
- 439 Published 2020 Feb 15.
- 9. Feng J, Huang X, Xu Q, et al. Pharmacological inhibition of the ACE/Ang-2/AT1
- 441 axis alleviates mechanical ventilation-induced pulmonary fibrosis. Int
- 442 *Immunopharmacol.* 2024;131:111855. doi:10.1016/j.intimp.2024.111855
- 443 10. Souza-Silva IM, Steckelings UM, Assersen KB. The role of vasoactive peptides in
- skin homeostasis-focus on adiponectin and the kallikrein-kinin system. Am J Physiol
- 445 *Cell Physiol.* 2023;324(3):C741-C756. doi:10.1152/ajpcell.00269.2022
- 446 11. Fang QQ, Wang XF, Zhao WY, et al. The source of ACE during scar formation is
- 447 from both bone marrow and skin tissue. FASEB J. 2018;32(9):5199-5208.
- 448 doi:10.1096/fj.201701575RRR
- 449 12. Rha EY, Kim JW, Kim JH, Yoo G. Angiotensin-Converting Enzyme Inhibitor,

- 450 Captopril, Improves Scar Healing in Hypertensive Rats. Int J Med Sci.
- 451 2021;18(4):975-983. Published 2021 Jan 1. doi:10.7150/ijms.50197
- 452 13. Demir CY, Ersoz ME, Erten R, Kocak OF, Sultanoglu Y, Basbugan Y. Comparison
- of Enalapril, Candesartan and Intralesional Triamcinolone in Reducing Hypertrophic
- 454 Scar Development: An Experimental Study. *Aesthetic Plast Surg.* 2018;42(2):352-361.
- 455 doi:10.1007/s00266-018-1073-6
- 456 14. Dow T, Selman T, Williams J, Bezuhly M. The Role of ACE-Inhibitors and ARBs
- 457 in reducing hypertrophic scarring following bilateral breast reduction. J Plast
- 458 *Reconstr Aesthet Surg.* 2023;78:1-3. doi:10.1016/j.bjps.2022.11.032
- 459 15. Mohammadi AA, Parand A, Kardeh S, Janati M, Mohammadi S. Efficacy of
- 460 Topical Enalapril in Treatment of Hypertrophic Scars. World J Plast Surg.
- 461 2018;7(3):326-331. doi:10.29252/wjps.7.3.326
- 462 16. Greif T, Alsawas M, Reid AT, et al. Targeting the Angiotensin Pathway in the
- Treatment of Cutaneous Fibrosis: A Systematic Review. *JID Innov.* 2023;3(6):100231.
- 464 Published 2023 Sep 12. doi:10.1016/j.xjidi.2023.100231
- 465 17. Bowden J, Holmes MV. Meta-analysis and Mendelian randomization: A review.
- 466 Res Synth Methods. Dec 2019;10(4):486-496. doi:10.1002/jrsm.1346
- 467 18. Lanlan Chen, Stephen Burgess, Shan Luo, Guoyue Lv First release of Mendelian
- randomisation book in Chinese: eGastroenterology 2023;1:e100043.
- 469 19. Noishiki C, Hayasaka Y, Yoshida R, Ogawa R. Over 90% of Childhood BCG
- 470 Vaccine-Induced Keloids in Japan Occur in Women. Dermatol Ther (Heidelb).
- 471 2023;13(5):1137-1147. doi:10.1007/s13555-023-00916-0
- 472 20. Arima J, Huang C, Rosner B, Akaishi S, Ogawa R. Hypertension: a systemic key
- 473 to understanding local keloid severity. Wound Repair Regen. 2015;23(2):213-221.
- 474 doi:10.1111/wrr.12277
- 475 21. Lanlan Chen, Guoyue Lv New horizons of human genetics in digestive
- diseases: eGastroenterology 2023;1:e100029.
- 477 22. Eldjarn GH, Ferkingstad E, Lund SH, et al. Large-scale plasma proteomics
- 478 comparisons through genetics and disease associations. *Nature*.
- 479 2023;622(7982):348-358. doi:10.1038/s41586-023-06563-x

- 480 23. Abdollahi MR, Huang S, Rodriguez S, et al. Homogeneous assay of rs4343, an
- 481 ACE I/D proxy, and an analysis in the British Women's Heart and Health Study
- 482 (BWHHS). Dis Markers. 2008;24(1):11-17. doi:10.1155/2008/813679
- 483 24. Yarmolinsky J, Díez-Obrero V, Richardson TG, et al. Genetically proxied
- 484 therapeutic inhibition of antihypertensive drug targets and risk of common cancers: A
- 485 mendelian randomization analysis. *PLoS Med.* 2022;19(2):e1003897. Published 2022
- 486 Feb 3. doi:10.1371/journal.pmed.1003897
- 487 25. Kehoe PG, Katzov H, Andreasen N, et al. Common variants of ACE contribute to
- 488 variable age-at-onset of Alzheimer's disease. Hum Genet. 2004;114(5):478-483.
- 489 doi:10.1007/s00439-004-1093-y
- 490 26. Gill D, Georgakis MK, Koskeridis F, et al. Use of Genetic Variants Related to
- 491 Antihypertensive Drugs to Inform on Efficacy and Side Effects. Circulation.
- 492 2019;140(4):270-279. doi:10.1161/CIRCULATIONAHA.118.038814
- 493 27. Hanchen Liu, Xiaoxi Zhang, Yu Zhou, Thanh N Nguyen, Lei Zhang, Pengfei Xing,
- 494 Zifu Li, Hongjian Shen, Yongxin Zhang, Weilong Hua, Hongye Xu, Xuan Zhu, Lei
- Chen, Qiao Zuo, Rui Zhao, Qiang Li, Dongwei Dai, Yongwei Zhang, Yi Xu, Qinghai
- 496 Huang, Jianmin Liu, Pengfei Yang, Association between blood pressure and different
- 497 antihypertensive drugs with outcome after ischemic stroke: A Mendelian
- 498 randomization study. *International Journal of Stroke*. 2023; 18(10): 1247-1254, doi:
- 499 10.1177/17474930231185695
- 500 28. Loh PR, Kichaev G, Gazal S, Schoech AP, Price AL. Mixed-model association for
- 501 biobank-scale datasets. *Nat Genet*. 2018;50(7):906-908.
- 502 doi:10.1038/s41588-018-0144-6
- 503 29. GTEx Consortium. The GTEx Consortium atlas of genetic regulatory effects
- 504 across human tissues. *Science*. 2020;369(6509):1318-1330.
- 505 doi:10.1126/science.aaz1776
- 506 30. Kurki MI, Karjalainen J, Palta P, et al. FinnGen provides genetic insights from a
- well-phenotyped isolated population [published correction appears in Nature. 2023
- 508 Feb 24;:]. *Nature*. 2023;613(7944):508-518. doi:10.1038/s41586-022-05473-8
- 509 31. Fairley S, Lowy-Gallego E, Perry E, Flicek P. The International Genome Sample

- Resource (IGSR) collection of open human genomic variation resources. *Nucleic*
- 511 Acids Res. 2020;48(D1):D941-D947. doi:10.1093/nar/gkz836
- 512 32. Yao S, Zhang M, Dong SS, et al. Bidirectional two-sample Mendelian
- randomization analysis identifies causal associations between relative carbohydrate
- 514 intake and depression. *Nat Hum Behav*. 2022;6(11):1569-1576.
- 515 doi:10.1038/s41562-022-01412-9
- 516 33. Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with
- 517 multiple genetic variants using summarized data. Genet Epidemiol. Nov
- 518 2013;37(7):658-65. doi:10.1002/gepi.21758
- 519 34. Hemani G, Zheng J, Elsworth B, et al. The MR-Base platform supports systematic
- causal inference across the human phenome. *Elife*. 2018;7:e34408. Published 2018
- 521 May 30. doi:10.7554/eLife.34408
- 522 35. Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent Estimation in
- 523 Mendelian Randomization with Some Invalid Instruments Using a Weighted Median
- 524 Estimator. *Genet Epidemiol*. May 2016;40(4):304-14. doi:10.1002/gepi.21965
- 525 36. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid
- 526 instruments: effect estimation and bias detection through Egger regression. Int J
- 527 Epidemiol. Apr 2015;44(2):512-25. doi:10.1093/ije/dyv080
- 528 37. Yao S, Zhang M, Dong SS, et al. Bidirectional two-sample Mendelian
- 529 randomization analysis identifies causal associations between relative carbohydrate
- 530 intake and depression. *Nat Hum Behav*. 2022;6(11):1569-1576.
- 531 doi:10.1038/s41562-022-01412-9
- 532 38. Stephen Burgess, Héléne Toinét Cronjé Incorporating biological and clinical
- 533 insights into variant choice for Mendelian randomisation: examples and
- principles: eGastroenterology 2024;2:e100042.
- 535 39. Burgess S, Thompson SG. Avoiding bias from weak instruments in Mendelian
- 536 randomization studies. Int J Epidemiol. Jun 2011;40(3):755-64.
- 537 doi:10.1093/ije/dyr036
- 538 40. Burgess S. Sample size and power calculations in Mendelian randomization with a
- 539 single instrumental variable and a binary outcome. Int J Epidemiol. Jun

- 540 2014;43(3):922-9. doi:10.1093/ije/dyu005
- 541 41. Zhu Z, Zhang F, Hu H, et al. Integration of summary data from GWAS and eQTL
- 542 studies predicts complex trait gene targets. Nat Genet. 2016; 48 (5):481-487.
- 543 doi:10.1038/ng.3538
- 544 42. Hedayatyanfard K, Ziai SA, Niazi F, Habibi I, Habibi B, Moravvej H. Losartan
- ointment relieves hypertrophic scars and keloid: A pilot study. Wound Repair Regen.
- 546 2018; 26 (4):340-343. doi:10.1111/wrr.12648
- 547 43. Ardekani GS, Aghaie S, Nemati MH, Handjani F, Kasraee B. Treatment of a
- 548 postburn keloid scar with topical captopril: report of the first case [published
- 549 correction appears in Plast Reconstr Surg. 2009 Jun;123(6):1898. Aghaie, Shahin
- 550 [corrected to Aghaei, Shahin]]. Plast Reconstr Surg. 2009; 123 (3):112e-113e.
- 551 doi:10.1097/PRS.0b013e31819a34db
- 552 44. Silva IMS, Assersen KB, Willadsen NN, Jepsen J, Artuc M, Steckelings UM. The
- role of the renin-angiotensin system in skin physiology and pathophysiology. Exp
- 554 *Dermatol.* 2020;29(9):891-901. doi:10.1111/exd.14159
- 555 45. Hedayatyanfard K, Haddadi NS, Ziai SA, et al. The renin-angiotensin system in
- cutaneous hypertrophic scar and keloid formation. *Exp Dermatol.* 2020;29(9):902-909.
- 557 doi:10.1111/exd.14154
- 558 46. Fagerberg L, Hallström BM, Oksvold P, et al. Analysis of the human
- 559 tissue-specific expression by genome-wide integration of transcriptomics and
- antibody-based proteomics. Mol Cell Proteomics. 2014; 13 (2):397-406.
- 561 doi:10.1074/mcp.M113.035600

Table 1 Detailed Information for Exposure GWAS Data

137	Exposur	NSN	\mathbb{R}^2	E	Sampl	Populatio	Sourc
IV	es	P	K ²	F	e size	n	e
serum_AC E	Serum ACE	30	0.24	376.28	35275	EUR	pQTL of Icelan d corhor t
ACE_SBP	ACE effect on SBP	2	6.47e-0 5	30.38	46976 7	EUR	UKB
ACE_DBP	ACE effect on DBP	2	6.43e-0 5	31.53	49046 9	EUR	UKB
serum_AC Ei	Serum ACE inhibitio n	14	0.34-0.3	2156.5-2594 .9	4174	EUR	pQTL of GER A
ACEi_SBP	ACE inhibitio n effect on SBP	2	0.28	759.90	75760 1	EUR	UKB and ICBP
SBP	SBP	293	4.37e-0 2	76.66	46976 7	EUR	UKB
DBP	DBP	283	4.56e-0 2	85.79	49046 9	EUR	UKB
Rs4291	ACE inhibitio	1	3.69e-0 4	276.00	74528 0	EUR	UKB and

	n effect						ICBP
	on SBP						
	BB		2.54~ 0		72900		UKB
BB	effect on 6	5	2.54e-0	188.00	73800 2	EUR	and
	SBP		4		2		ICBP
	CCB		5 26 a 0		72650		UKB
CCB	effect on 2	24	5.26e-0 3	176.32	73650 8	EUR	and
	SBP		3		8		ICBP
	ARB		2.00- 0		75760		UKB
ARB	effect on 1	1	3.99e-0	30.25	75760	EUR	and
	SBP		5		1		ICBP

GERA: Genetic Epidemiology Research on Adult Health and Aging

ICBP: International Consortium of Blood Pressure-Genome Wide Association Studies

Table 2 Detailed Information for Outcome GWAS Data

Dhanotyna	UKB-id	Sample	Ncase	Ncontrol	Couras	Population
Phenotype	UKD-IU	size	Nease	Neominor	Source	ropulation
Hypertrophic scar	-	323,197	1294	321903	Finngen	EUR
Keloid	701.4	404,486	216	402139	UKB	EUR
Skin fibrosis and scar	701.2	404,486	2245	402141	UKB	EUR
condition	701.2	404,480	2345	402141	UKD	EUK
Skin fibrosis and scar		322,794	901	221002	Einnaan	ELID
condition	-	322,794	891	321903	Finngen	EUR

Table 3 Serum ACE and Skin Fibrotic Diseases

IV	Expo sure	Outco me	Pleiotr opy	Heterog eneity	Meth od	Bet a	SE	P-v alue	OR (95%CI
rs4343	Seru m ACE inhibi tion	Hypert rophic Scar (FinnG en)	NA	NA	Wald ratio	0.04	0.0 591	0.46 07	1.0446 (0.9303- 1.1729)
rs4343	seru m ACE inhibi tion	Keloid (UKB)	NA	NA	Wald ratio	0.11 59	0.1 540	0.45	1.1229 (0.8304- 1.5184)
rs4343	Seru m ACE inhibi tion	Skin Fibrosi s and Scar Conditi on (UKB)	NA	NA	Wald ratio	-0.0 476	0.0 460	0.30 09	0.9535 (0.8712- 1.0435)
rs4343	Seru m ACE inhibi tion	Skin Fibrosi s and Scar Conditi on (FinnG en)	NA	NA	Wald	-0.0 747	0.0 708	0.29	0.928 (0.8077- 1.0662)

serum_ ACE	Seru m ACE	Hypert rophic Scar (FinnG en)	0.8122	0.4179	IVW- FE	-0.0 412	0.0 538	0.44	0.9596 (0.8636- 1.0663)
					IVW- MRE	-0.0 412	0.0 546	0.45	0.9596 (0.8622- 1.0681)
					Weig hted Media n	0.02 56	0.0 765	0.73 75	1.026 (0.8831- 1.192)
					Simpl e Mode	0.06 95	0.1 245	0.58 08	1.072 (0.8399- 1.3682)
					Weig hted Mode	0.01 46	0.0 732	0.84	1.0147 (0.8792- 1.1712)
serum_ ACE	Seru m ACE	Keloid (UKB)	0.8346	0.9486	IVW- FE	0.02 72	0.1 387	0.84	1.0276 (0.783-1. 3487)
					IVW- MRE	0.02 72	0.1 086	0.80	1.0276 (0.8306- 1.2714)
					Weig hted Media n Simpl	0.13	0.1 899 0.3	0.49 09 0.71	1.1397 (0.7855- 1.6536) 0.881
					Simbi	-0.1	0.5	0.71	0.001

		Skin			e Mode Weig hted Mode	267 0.10 98	4490.1986	610.5845	(0.4481- 1.7322) 1.1161 (0.7563- 1.6471)
serum_ ACE	Seru m ACE	Fibrosi s and Scar Conditi on (UKB)	0.5314	0.5025	IVW- FE	-0.0 246	0.0 420	0.55 75	0.9757 (0.8986- 1.0594)
					IVW- MRE	-0.0 246	0.0 415	0.55	0.9757 (0.8995- 1.0583)
					Weig hted Media n	-0.0 738	0.0 579	0.20	0.9289 (0.8292- 1.0406)
					Simpl e Mode	-0.0 446	0.0 928	0.63 44	0.9564 (0.7974- 1.1471)
		Ql.in			Weig hted Mode	-0.0 692	0.0 590	0.25	0.9332 (0.8312- 1.0476)
serum_ ACE	Seru m ACE	Skin Fibrosi s and Scar	0.4761	0.9259	IVW- FE	0.10	0.0 643	0.11 85	1.1055 (0.9747- 1.2539)

\sim	1	•	. •
('An	А	1	t1
Con	u	1	u

on

(FinnG

en)

		,							
					IVW- MRE	0.10	0.0 518	0.05 26	1.1055 (0.9989- 1.2236)
					Weig hted Media n	0.05 72	0.0 864	0.50 78	1.0589 (0.8939- 1.2544)
					Simpl e Mode	-0.0 115	0.1 317	0.93	0.9886 (0.7637- 1.2797)
					Weig hted Mode	0.04	0.0 838	0.62 56	1.0422 (0.8844- 1.2282)
serum_ ACEi	seru m ACE inhibi tion	Hypert rophic Scar (FinnG en)	0.6886	0.4511	IVW- FE	-0.0 019	0.0 394	0.96 07	0.9981 (0.9238- 1.0783)
					IVW- MRE	-0.0 019	0.0 393	0.96 06	0.9981 (0.924-1. 078)
					Weig hted Media n	-0.0 199	0.0 504	0.69	0.9803 (0.8881- 1.0821)

	Seru				Simpl e Mode Weig hted Mode	-0.1 264 0.01 41	0.0 872 0.0 555	0.17 26 0.80 37	0.8812 (0.7428- 1.0454) 1.0142 (0.9097- 1.1307)
serum_ ACEi	m ACE inhibi tion	Keloid (UKB)	0.6304	0.6612	IVW- FE	0.04 65	0.1 064	0.66 24	1.0476 (0.8503- 1.2906)
					IVW- MRE	0.04 65	0.0 952	0.62 54	1.0476 (0.8693- 1.2625)
					Weig hted Media n	0.11	0.1	0.39 87	1.1189 (0.8619- 1.4525)
					Simpl e Mode	0.02 73	0.2	0.90 77	1.0277 (0.6535- 1.6163)
	Seru	Chin			Weig hted Mode	0.11	0.1 456	0.45 14	1.1197 (0.8417- 1.4894)
serum_ ACEi	m ACE inhibi tion	Skin Fibrosi s and Scar Conditi	0.6263 33556	0.13664 7881	IVW- FE	-0.0 311	0.0 321	0.33	0.9693 (0.9102- 1.0323)

on (UKB)

		(UKB)							
					IVW- MRE Weig	-0.0 311	0.0 384	0.41 72	0.9693 (0.8991- 1.0451) 0.9621
					hted Media n	-0.0 387	0.0 405	0.33 95	(0.8887- 1.0415)
					Simpl e Mode	0.05 18	0.0 938	0.59	1.0531 (0.8763- 1.2656)
					Weig hted Mode	-0.0 386	0.0 443	0.39 96	0.9622 (0.8821- 1.0494)
serum_ ACEi	Seru m ACE inhibi tion	Skin Fibrosi s and Scar Conditi on (FinnG en)	0.1366	0.7004	IVW- FE	-0.0 661	0.0 473	0.16 21	0.9361 (0.8532- 1.0269)
					IVW- MRE	-0.0 661	0.0 410	0.10 70	0.9361 (0.8638- 1.0144)
					Weig hted Media	-0.0 599	0.0 603	0.32 08	0.9419 (0.8368- 1.0601)

n				
Simpl	0.01	0.1	0.00	1.0135
	0.01	0.1	0.89	(0.0211
e	34	012	70	(0.8311-
Mode	51	012	70	1.2358)
Weig				0.9581
1.4.1	-0.0	0.0	0.51	(0.0452
hted	428	640	67	(0.8452-
Mode	720	0-10	07	1.0862)

Table 4 ACE Effect on Blood Pressure and Skin Fibrotic Diseases

137	Expo	Outco	Pleiot	Hetero	Meth	Bet	QT:	P-v	OR
IV	sure	me	ropy	geneity	od	a	SE	alue	(95%CI)
rs429 1	Effec t of ACE inhib ition on SBP	Hypert rophic Scar (FinnG en)	NA	NA	Wald	0.0 717	0.1	0.59	1.0743 (0.8264-1.3 965)
rs429 1	Effec t of ACE inhib ition on SBP	Skin Fibrosi s and Scar Conditi on (FinnG en)	NA	NA	Wald	0.1 193	0.1 604	0.45 68	1.1268 (0.8228-1.5 429)
ACE_ SBP	Effec t of ACE on SBP	Hypert rophic Scar (FinnG en)	NA	NA	Wald	1.7 460	3.1 452	0.57 88	5.7315 (0.0121-272 5.9807)
ACE_ SBP	Effec t of ACE on SBP	Skin Fibrosi s and Scar Conditi on	NA	NA	Wald ratio	5.1 906	3.7 723	0.16 88	179.5763 (0.1105-291 939.3434)

		(FinnG							
		en)							
	Effec	Hypert							
ACE_	t of	rophic			Wald	1.7	3.1	0.57	5.7621
DBP	ACE	Scar	NA	NA	ratio	513	548	88	(0.0119-279
DDI	on	(FinnG			Tatio	313	J 4 0	00	2.3439)
	DBP	en)							
		Skin							
	Effec	Fibrosi							
	t of	s and							182.433
ACE_	ACE	Scar	NA	NA	Wald	5.2	3.7	0.16	(0.1097-303
DBP	on	Conditi	INA	NA	ratio	064	838	88	326.6091)
	DBP	on							320.0091)
	DDI	(FinnG							
		en)							
	Effec								
	t of	Hypert							
ACEi	ACE	rophic			IVW-	0.0	0.1	0.44	1.0948
_SBP	inhib	Scar	NA	0.8594	FE	905	192	75	(0.8667-1.3
_5D1	ition	(FinnG			1 L	703	1/2	75	829)
	on	en)							
	SBP								
					IVW-	0.0	0.0	0.00	1.0948
					MRE	905	211	00	(1.0504-1.1
					WIKE	703	211	00	41)
	Effec	Skin							1.2292
ACEi	t of	Fibrosi	NA	0.4739	IVW-	0.2	0.1	0.14	(0.9289-1.6
_SBP	ACE	s and	- 14 4	0.1707	FE	063	429	88	265)
	inhib	Scar							200)

ition Conditi
on on
SBP (FinnG
en)

IVW- 0.2 0.1 0.04 (1.0057-1.5 MRE 063 023 38 022)

Table 5 ACE Expression in Local Skin Tissue and Skin Fibrotic Diseases

Tiggue	Outco	Ge	Probe	Тор	A	A	Fr	B_s	Se_	P_s	P_h	NSNP_
Tissue	me	ne	_bp	snp	1	2	eq	mr	smr	mr	eidi	heidi
Supra pubic skin	Hypetr ophic scar	A CE	6155 4422	Rs4 311	С	Т	0. 50	-0.1 3	0.23	0.5	0.77	8
Supra pubic skin	Keloid	A CE	6155 4422	Rs4 311	С	Т	0. 50	-0.6 3	0.62	0.3	0.95	8
Supra pubic skin	Skin fibrosis and scar conditi on (UKB)	A CE	6155 4422	Rs4 311	C	Т	0. 50	0.0	0.18	0.7	0.47	8
Supra pubic skin	Skin fibrosis and scar conditi on (Finng en)	A CE	6155 4422	Rs4 311	C	Т	0. 50	0.1	0.28	0.5	0.88	8
Leg	Hypetr ophic scar	A CE	6155 4422	Rs4 292	Т	С	0. 63	0.1 4	0.21	0.5	0.22	11
Leg	Keloid	A CE	6155 4422	Rs4 292	T	С	0. 63	-0.3 6	0.55	0.5 2	1.00	11

	Skin											
	fibrosis											
	and	A	6155	DαA			0	0.0		0.9		
Leg	scar	CE		292	T	C	63		0.17	0.9	0.35	11
	conditi	CE	4422	292			03	2		U		
	on											
	(UKB)											
	Skin											
	fibrosis											
	and											
Leg	scar	A	6155	Rs4	т	C	0.	0.1	0.25	0.4	0.95	11
Leg	conditi	CE	4422	292	1	C	63	8	0.23	7	0.93	11
	on											
	(Finng											
	en)											

Table 6 Blood Pressure and Skin Fibrotic Diseases

137	Expo	Outco	Pleiot	Heterog	Metho	D.4-	QT.	P-va	OR
IV	sure	me	ropy	eneity	d	Beta	SE	lue	(95%CI)
		Hypertr ophic							0.6925
SB	SBP	Scar	0.2526	0.0588	IVW-	-0.3	0.1	0.00	(0.54-0.8
P	221	(FinnGe	0.2020	3.32 33	FE	675	269	38	881)
		n)							001)
		11)			IVW-	-0.3 675	0.1 353	0.00 66	0.6925 (0.5312-0
					Weigh				.9028)
					ted	-0.3	0.2	0.08	(0.4635-1
					Media	594	090	55	.0515)
					n				,
					Simple	-0.6	0.6	0.32	0.5372 (0.1571-1
					Mode	215	273	27	.8368)
					Weigh ted	-0.4 694	0.4 676	0.31	0.6254 (0.2501-1 .5637)
		Skin							
		Fibrosis							
SB	SBP	and Scar	0.1628	0.6433	IVW-	-0.1	0.1	0.46	0.8953 (0.6647-1
P	~	Conditi on	5 9 - 9	3.2.00	FE	106	519	65	.2058)
		(FinnGe							
		n)							

					IVW- MRE Weigh	-0.1 106	0.1 494	0.45 89	0.8953 (0.6681-1 .1998)
					ted Media	-0.1 238	0.2 456	0.61 42	0.8835 (0.5459-1 .4299)
					Simple Mode	0.03 69	0.6 428	0.95 43	1.0375 (0.2944-3 .6571)
					Weigh ted Mode	-0.2 355	0.4 634	0.61 17	0.7902 (0.3186-1 .9598)
D BP	DBP	Hypertr ophic Scar (FinnGe n)	0.1156	0.0278	IVW- FE	-0.0 655	0.1 234	0.59 55	0.9366 (0.7354-1 .1928)
					IVW- MRE	-0.0 655	0.1 335	0.62	0.9366 (0.721-1. 2167)
					Weigh ted Media n	-0.1 678	0.1 954	0.39	0.8455 (0.5765-1 .24)
					Simple Mode	-0.3 302	0.5	0.57	0.7188 (0.2273-2 .2724)
					Weigh	-0.1	0.4	0.64	0.8188

					ted Mode	999	320	39	(0.3511-1
		Skin							
		Fibrosis							
		and							0.9721
D	DBP	Scar	0.9617	0.7486	IVW-	-0.0	0.1	0.84	(0.7277-1
BP	DDI	Conditi	0.7017	0.7400	FE	283	477	79	.2985)
		on							.2963)
		(FinnGe							
		n)							
					IVW-	-0.0	0.1	0.84	0.9721
									(0.734-1.
					MRE	283	433	33	2873)
					Weigh				0.0065
					ted	-0.0	0.2	0.68	0.9065
					Media	982	395	19	(0.5669-1
					n				.4495)
					G: 1	0.1	0.6	0.00	0.8547
					Simple	-0.1	0.6	0.80	(0.2394-3
					Mode	570	492	91	.0509)
					Weigh	0.2	0.4	0.74	0.7616
					ted	-0.2	0.4	0.54	(0.3159-1
					Mode	723	491	47	.8365)

Table 7 Other Antihypertension Drugs' Effect on Blood Pressure and Skin Fibrotic Diseases

IV	Expo	Outco	Pleiot	Heterog	Metho	Beta	SE	P-va	OR
	sure	me	ropy	eneity	d			lue	(95%CI)
	Effect	Hypertr							
A	of	ophic			Wald	-0.1	0.2	0.49	0.8603
R	ARBs	Scar	NA	NA					(0.5589-1
В	on	(FinnGe			ratio	505	200	40	.3241)
	SBP	n)							
		Skin							
		Fibrosis							
	Effect	and							
A	of	Scar			Wald	0.32	0.2	0.22	1.3799
R	ARBs	Conditi	NA	NA	ratio	20	638	22	(0.8228-2
В	on	on							.3142)
	SBP	(FinnGe							
		n)							
	Effect	Hypertr							
	of	ophic							1.0648
В	BBs	Scar	0.4511	0.0085	IVW-	0.06	0.0	0.28	(0.9497-1
В	on	(FinnGe	0.4311	0.0003	FE	27	583	21	.1938)
	SBP	,							.1930)
	SDF	n)							1.0648
					IVW-	0.06	0.1	0.54	
					MRE	27	027	12	(0.8706-1
									.3022)
					Weigh				1.0152
					ted	0.01	0.0	0.84	(0.8741-1
					Media	50	763	37	.179)
					n				,


					Simple Mode Weigh ted Mode	0.05 01 -0.0 226	0.1 072 0.0 822	0.65 98 0.79 47	1.0514 (0.8522-1 .2971) 0.9777 (0.8321-1 .1487)
B B	Effect of BBs on SBP	Skin Fibrosis and Scar Conditi on (FinnGe n)	0.7791	0.6579	IVW- FE	0.16 88	0.0 696	0.01 53	1.1839 (1.033-1. 3569)
					IVW- MRE	0.16 88	0.0 563	0.00 27	1.1839 (1.0602-1 .3221)
					Weigh ted Media n	0.15	0.0 827	0.06 91	1.1622 (0.9883-1 .3667)
					Simple Mode	0.18 08	0.1 287	0.21 91	1.1982 (0.931-1. 5421)
_	7.00				Weigh ted Mode	0.14 96	0.0 964	0.18	1.1614 (0.9614-1 .4031)
C C	Effect of	Hypertr ophic	0.3079	0.5962	IVW- FE	0.05	0.0 322	0.06 84	1.0605 (0.9956-1

В	CCBs	Scar							.1297)
	on	(FinnGe							
	SBP	n)							
					IVW-	0.05	0.0	0.05	1.0605
					MRE	88	305	43	(0.9989-1
					Weigh				1.0717
					ted	0.06	0.0	0.12	
					Media	93	447	12	(0.9818-1
					n				.10///
					Simple	0.11	0.0	0.18	1.1168
					Mode	05	813	84	(0.9524-1
					Weigh	0.07	0.0	0.21	1.0829
					ted	96	628	88	(0.9574-1
		Skin			Mode				.2248)
	Effect	Fibrosis							
C	of	and Scar			IVW-	-0.0	0.0	0.14	0.946
C	CCBs	Conditi	0.7805	0.3859	FE	556	386	99	(0.8771-1
В	on	on			12		200		.0203)
	SBP	(FinnGe							
		n)							
		,			IVW-	-0.0	0.0	0.16	0.946
					MRE	556	397	17	(0.8751-1
					*** * *	0.0	0.0	0.22	.0225)
					Weigh	-0.0	0.0	0.23	0.937
					ted	651	549	54	(0.8415-1

Media				.0433)
n				
Simple	-0.0	0.0	0.51	0.9456
Mode	559	850	81	(0.8005-1
Weigh	-0.0	0.0	0.28	0.9327
ted	696	628	0.28	(0.8247-1
Mode	070	020	00	.0549)

Local ACE expression in skin SMR Selection of IVs: p < 5e-8, r² <0.1, within ±5 Mb of ACE gene Skin fibrotic diseases Serum ACE/ACEi Hypertrophic scar, keloid, skin Two Sample MR fibrosis and scar condition Selection of IVs: p < 5e-8, 5000 kb, r^2 <0.1, within ±100 kb of ACE gene Two Sample MR Known causal Selection of IVs: p < 5e-8 for both relationship ACE and SBP/DBP, 5000 kb, r^2 <0.1, within ±100 kb of ACE gene Blood pressure, SBP/DBP Skin fibrotic diseases Antihypertention drugs Hypertrophic scar, keloid, skin ARBs, BBs, CCBs Two Sample MR fibrosis and scar condition Selection of IVs: p < 5e-8 for SBP, 5000 kb, r2 < 0.1, within ±100 kb or promoters/enhancers of target gene Two Sample MR Known causal Selection of IVs: p < 5e-8 for relationship SBP/DBP, 10000 kb, r2 < 0.0001 Blood pressure, SBP/DBP

Exposure	Outcome	Method		OR(95% CI)	P.value
Serum ACE inhibition (rs4343)	Hypertrophic Scar (FinnGen)	Wald ratio	+	1.04 (0.93 to 1.17)	0.4607
Serum ACE inhibition (rs4343)	Keloid (UKB)	Wald ratio		1.12 (0.83 to 1.52)	0.4517
Serum ACE inhibition (rs4343)	Skin Fibrosis and Scar Condition (UKB)	Wald ratio	=	0.95 (0.87 to 1.04)	0.3009
Serum ACE inhibition (rs4343)	Skin Fibrosis and Scar Condition (FinnGen)	Wald ratio	-=-	0.93 (0.81 to 1.07)	0.2916
Serum ACE	Hypertrophic Scar (FinnGen)	IVW-FE	+	0.96 (0.86 to 1.07)	0.4436
		IVW-MRE	=	0.96 (0.86 to 1.07)	0.4507
Serum ACE	Keloid (UKB)	IVW-FE	-	1.03 (0.78 to 1.35)	0.8443
		IVW-MRE	-	1.03 (0.83 to 1.27)	0.8020
Serum ACE	Skin Fibrosis and Scar Condition (UKB)	IVW-FE	+	0.98 (0.90 to 1.06)	0.5575
		IVW-MRE	+	0.98 (0.90 to 1.06)	0.5526
Serum ACE	Skin Fibrosis and Scar Condition (FinnGen)	IVW-FE	=-	1.11 (0.97 to 1.25)	0.1185
		IVW-MRE	-	1.11 (1.00 to 1.22)	0.0526
Serum ACE inhibition	Hypertrophic Scar (FinnGen)	IVW-FE	+	1.00 (0.92 to 1.08)	0.9607
		IVW-MRE	+	1.00 (0.92 to 1.08)	0.9606
Serum ACE inhibition	Keloid (UKB)	IVW-FE	-	1.05 (0.85 to 1.29)	0.6624
		IVW-MRE	-	1.05 (0.87 to 1.26)	0.6254
Serum ACE inhibition	Skin Fibrosis and Scar Condition (UKB)	IVW-FE	+	0.97 (0.91 to 1.03)	0.3321
		IVW-MRE	+	0.97 (0.90 to 1.05)	0.4172
Serum ACE inhibition	Skin Fibrosis and Scar Condition (FinnGen)	IVW-FE	=	0.94 (0.85 to 1.03)	0.1621
		IVW-MRE	0.5 1	0.94 (0.86 to 1.01) 7 2	0.1070



Drugs	Exposure	Outcome	Method	OR(95% CI)	P.value
ARB	Effect of ARBs on SBP	Hypertrophic Scar (FinnGen)	Wald ratio —■	0.86 (0.56 to 1.32)	0.4940
ARB	Effect of ARBs on SBP	Skin Fibrosis and Scar Condition (FinnGen)	Wald ratio	→ 1.38 (0.82 to 2.31)	0.2222
BB	Effect of BBs on SBP	Hypertrophic Scar (FinnGen)	IVW-FE =-	1.06 (0.95 to 1.19)	0.2821
			IVW-MRE	1.06 (0.87 to 1.30)	0.5412
			Weighted Median -	1.02 (0.87 to 1.18)	0.8437
			Simple Mode -	1.05 (0.85 to 1.30)	0.6598
			Weighted Mode -	0.98 (0.83 to 1.15)	0.7947
BB	Effect of BBs on SBP	Skin Fibrosis and Scar Condition (FinnGen)	IVW-FE -■-	1.18 (1.03 to 1.36)	0.0153
			IVW-MRE -■-	1.18 (1.06 to 1.32)	0.0027
			Weighted Median	1.16 (0.99 to 1.37)	0.0691
			Simple Mode	1.20 (0.93 to 1.54)	0.2191
			Weighted Mode	1.16 (0.96 to 1.40)	0.1815
CCB	Effect of CCBs on SBP	Hypertrophic Scar (FinnGen)	IVW-FE =	1.06 (1.00 to 1.13)	0.0684
			IVW-MRE	1.06 (1.00 to 1.13)	0.0543
			Weighted Median	1.07 (0.98 to 1.17)	0.1212
			Simple Mode	1.12 (0.95 to 1.31)	0.1884
			Weighted Mode -■-	1.08 (0.96 to 1.22)	0.2188
CCB	Effect of CCBs on SBP	Skin Fibrosis and Scar Condition (FinnGen)	IVW-FE ■	0.95 (0.88 to 1.02)	0.1499
			IVW-MRE	0.95 (0.88 to 1.02)	0.1617
			Weighted Median -	0.94 (0.84 to 1.04)	0.2354
			Simple Mode -	0.95 (0.80 to 1.12)	0.5181
			Weighted Mode -■-	0.93 (0.82 to 1.05)	0.2800
			0.5 1	2	
					
			Less susceptible to diseases More s	susceptible to diseases	